Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
Status:
Completed
Trial end date:
2014-12-23
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy
and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects
with severe hypertriglyceridemia. The study consists of an approximately 8-week screening
period that includes a diet and lifestyle stabilization and washout period and a 12-week
treatment period.